個案總覽
依發行單位、學門或關鍵字，找到適合的教學個案。
-
AbbVie
AbbVie made headlines in March 2015 when it announced its $21 billion acquisition of Pharmacyclics. AbbVie, a research-based pharmaceutical company was founded in 2013 when Abbott split into AbbVie and Abbott Laboratories. Pharmacyclics is a biotechnology company that had received FDA approval in late 2013 for its flagship asset Imbrivica (ibrutinib), a biologic treatment for chronic lymphocytic leukemia and two other even rarer blood malignancies. Entering it's second year on the market, Imbrivica was considered a breakthrough, with revenue expectations of $1 billion in 2015. At the time of the acquisition, AbbVie received more than 60% of its sales from the biologic drug Humira, a biologic agent used to treat several autoimmune diseases and malignancies. However, Humira would soon lose patent protection and face competition from the new class of follow-on biologics, or biosimilars.